Giles Platford Discusses Strengthening the Plasma Ecosystem for Patients Worldwide at PPF2025
Giles Platford, President, Plasma-Derived Therapies Business Unit at Takeda and Chair of the Global Executive Board at PPTA, shared on LinkedIn:
”At this year’s Plasma Protein Forum, it was rewarding to join colleagues and partners from across the industry in conversations focused on strengthening sustainability of the plasma ecosystem, and advancing access to PDTs.
We heard from many compelling speakers, and I appreciated the contributions of my Takeda colleagues in sharing their expertise to advance knowledge across the value chain.
Thomas R. Kreil offered important perspectives on innovations in plasma testing and manufacturing, while Thomas Szatkowski demonstrated tangible examples of how we are applying AI and machine learning to transform the way we collect, process and deliver plasma therapies.
The meeting also placed considerable emphasis on navigating the regulatory uncertainties we face both in the US and globally, centering, as always, the needs of patients and donors.
Thank you to the Plasma Protein Therapeutics Association (PPTA) for convening such an engaging and forward-looking forum.
These moments of shared learning and collaboration are essential as we work together to ensure more patients can benefit from the life-saving potential of plasma.”
More from PPF2025 featured in Hemostasis Today.
-
Oct 17, 2025, 08:37Salome Mekhuzla Invites You to Join WHO Essential Medicines List 2025 Updates Webinar on Hemophilia and VWD
-
Oct 17, 2025, 08:36Plasma Protein Forum 2025: From Anti-D Plasma and Blood Supply Incentives to the Future of AI
-
Oct 17, 2025, 08:33Hossam El Benawi to Present Latest Mayo Clinic Insights on Left Ventricular Thrombus at AHA 2026
-
Oct 17, 2025, 08:32Brian O Mahony Invites You to Irish Haemophilia Society Webinar Series
-
Oct 17, 2025, 08:30Thomas Reiser Invites You to Take A Survey on AI and Machine Learning From ISTH
-
Oct 17, 2025, 09:00Shreya Agarwal: We Describe Patients With PLG Mutations Who Experienced Recurrent TMA
-
Oct 17, 2025, 08:41Review of Community-Based Stroke Rehabilitation in LMICs from Dominique Cadilhac's Team
-
Oct 16, 2025, 04:43Michael Makris Invites You to The Research Recap on FEIBA Use in Patients on Emicizumab
-
Oct 16, 2025, 04:41Suhasini Sil on Impact of AMBM Red Cell Transfusions in Improving Transfusion Outcomes
-
Oct 16, 2025, 04:37Hinde El Otmani's Team Explores Plasmin-Mediated Proteolysis of von Willebrand Factor in Acutely Ill Patients
-
Oct 14, 2025, 05:26Ryan C. Heniford: Every Thrombus Prevented Is a Patient Protected
-
Oct 13, 2025, 04:48Archil Jaliashvili showcases how BHOC builds on Hemopure’s success to revolutionize surgery and care
-
Oct 13, 2025, 02:46Flora Peyvandi: First Proposed Blood Test for Chronic Fatigue Syndrome - What Scientists Think
-
Oct 13, 2025, 02:44Silvio Maresca: Honored to be part of this international research project - ThrombUS+
-
Oct 10, 2025, 12:25Robert Lewis: T Cells Are Wonderful - But They Can't Do Everything
-
Oct 17, 2025, 08:52Erica Sparkenbaugh: Shout Out to My Doctoral Student Kylie Hutchison for Her Outstanding Oral Presentation
-
Oct 17, 2025, 08:45Shamee Shastry Shares Lean and Six Sigma in Transfusion Medicine Training Program's Success
-
Oct 16, 2025, 04:44Giles Platford Discusses Strengthening the Plasma Ecosystem for Patients Worldwide at PPF2025
-
Oct 16, 2025, 04:27Ranjeet Ajmani: Southeast Asia - 25% of The Global Population Contributes Less than 2% of The Global Plasma Supply
-
Oct 15, 2025, 05:59Courtney Lawrence: I've Got A Place at American Red Cross for You!